Skip to content
#gene editing Review Open access

Gene and nucleic acid therapies for MMUT-deficient methylmalonic acidemia: from AAV-mediated gene addition to LNP-mediated mRNA delivery and precision genome editing

Aug 2026 · Orphanet Journal of Rare Diseases · 0 citations

TL;DR

Current therapeutic evidence is concentrated primarily in MMUT- deficient isolated MMA, and further progress will require safer and more durable delivery platforms, improved tissue targeting, robust long-term safety assessment, clinically meaningful endpoints, and careful evaluation of accessibility and cost.

Abstract

Methylmalonic acidemia (MMA) comprises a heterogeneous group of inherited metabolic disorders characterized by the accumulation of methylmalonic acid and related toxic metabolites. Among these conditions, isolated MMA caused by pathogenic variants in MMUT is the disease subtype in which gene and nucleic acid therapies have been investigated most extensively. Current management, including dietary protein restriction, L-carnitine supplementation, acute decompensation management, assessment of cobalamin responsiveness, and liver or combined liver-kidney transplantation, can improve metabolic stability but often remains insufficient to prevent recurrent metabolic crises, neurological injury, renal impairment, and reduced quality of life. This review summarizes the development of gene and nucleic acid therapies for MMUT- deficient MMA over the past three decades. The field has evolved from cellular correction and early nonviral, adenoviral, retroviral, and lentiviral approaches to adeno-associated virus (AAV)-mediated MMUT gene addition, albumin ( ALB )-locus genome editing, lipid nanoparticle (LNP)-mediated MMUT mRNA delivery, central nervous system and extrahepatic targeting, antisense-based splicing correction, mitochondrial protein delivery, and emerging precision-editing strategies. AAV8, AAV9, AAV44.9, and nuclease-free ALB -locus editing studies have provided a substantial preclinical foundation, while mRNA-based therapy and liver-directed genome editing have begun to enter clinical translation. However, AAV immunotoxicity, pre-existing neutralizing antibodies, redosing barriers, dilution of episomal transgene expression in the growing pediatric liver, incomplete correction of extrahepatic tissues, delivery safety, treatment burden, and cost remain major obstacles. Current therapeutic evidence is concentrated primarily in MMUT- deficient isolated MMA. Further progress will require safer and more durable delivery platforms, improved tissue targeting, robust long-term safety assessment, clinically meaningful endpoints, and careful evaluation of accessibility and cost.

Read PDF

Similar papers

#gene editing Review Sep 2026

Unlocking non-model organisms with CRISPR-Cas: A roadmap for sustainable biotechnology.

It is concluded that bridging the gap between foundational CRISPR research and its real-world applications is imperative and future efforts should focus on democratizing tools via open-source platforms, advancing delivery systems, and fostering sustainable innovation through synthetic biology integration to fully realize the transformative potential of genome editing in organisms beyond model organisms.

S. Sarsaiya, Archana Jain, Jishuang Chen et al. · 2 citations
#gene editing Review Open access Aug 2026

Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies

This review summarizes emerging therapeutic strategies for EOC, their mechanisms of action, and their potential to overcome treatment resistance, and covers molecularly targeted therapies, immunotherapies, metabolic and epigenetic approaches, cellular and gene therapies, targeted drug-delivery systems, and locoregional and physical modalities.

Zofia Pietrasik, Mikołaj Kapała, Joanna Pietrasik et al. · 0 citations
#gene editing Review Open access Aug 2026

Environmental Risk Assessment and Confinement of Genetically Engineered Trees with an Emphasis on Vegetative Reproduction.

Genetic engineering (GE) and gene editing may endow traits to trees such as increased biomass and the production of novel biomaterials. Long-lived organisms such as trees might be subject to biotechnology-related risks that could be different than those of annual row crops. Those risks could be relevant to production in engineered plantations and beyond plantations to natural forests. Therefore, appropriate risk regulation is important to assure biosafety of commercialized engineered trees. In addition to gene flow via sexual reproduction, vegetative reproduction might play an additional role in environmental "exposure" risk relative to transgene dispersal in GE tree plantations. While vegetative reproduction is beneficial for preserving desired genetic traits during tree propagation, it may lead to proximal clonal spread in the field. Although the environmental risks associated with vegetative reproduction of GE trees are recognized in commercial forestry, there are few field-based environmental risk assessment (ERA) studies on dispersal risks of self-propagated GE trees. GE or gene editing of target genes involved in the vegetative propagation processes may be useful to mitigate environmental risks of clonal spread through vegetative reproduction. This review provides updates for recent field test results of GE and gene edited trees. Gene candidates related to vegetative reproduction including adventitious shooting (AS) and adventitious rooting (AR) are discussed herein as a means to mitigate unintended clonal spread from GE tree plantations.

Yongil Yang, C. N. Stewart · 0 citations
#gene editing Open access Aug 2026

Programmable RNA targeting with clustered regularly interspaced short palindromic repeats (CRISPR) effector Cas7-11 in zebrafish embryos and mammalian cells

Findings establish Cas7-11 as a precise and efficient RNA knockdown tool for functional studies in embryonic development and stem cell biology, providing a versatile alternative to DNA-based gene-editing approaches.

Huan Yan, Imtiaz Ul Hassan, Kai Yan et al. · 0 citations

Related blog posts

MIT News · Artificial Intelligence Aug 17, 2026

Q&A: Rethinking how innovation happens

In his latest book, Professor Eugene Fitzgerald examines the forces that turn breakthroughs into value — and why innovation resists simple formulas.